- Home
- ACRS
as 05-30-2025 4:00pm EST
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 127.6M | IPO Year: | 2015 |
| Target Price: | $9.71 | AVG Volume (30 days): | 709.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $5.17 | Next Earning Date: | 05-08-2025 |
| Revenue: | $17,777,000 | Revenue Growth: | -42.87% |
| Revenue Growth (this year): | -72.1% | Revenue Growth (next year): | 14.59% |
Latest Aclaris Therapeutics Inc. News
ACRS Breaking Stock News: Dive into ACRS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
MT Newswires
3 days ago
Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target
Simply Wall St.
21 days ago
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
22 days ago
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Zacks
23 days ago
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Associated Press Finance
23 days ago
Aclaris: Q1 Earnings Snapshot
GlobeNewswire
23 days ago
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
MT Newswires
a month ago
Aclaris Therapeutics Names Jesse Hall Chief Medical Officer
Compare ACRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRS Aclaris Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.